Glenmark launches kidney cancer treatment drug in India priced 96% lower than innovator brand
In a regulatory filing, Glenmark Pharma said it launched "SUTIB, the
generic version of Sunitinib oral capsules to treat kidney cancer in
India. The drug is launched at a MRP that is approximately 96 per cent
lower than the MRP (maximum retail price) compared to the innovator
brand, priced at Rs 7,000 (50 mg), Rs 3,600 (25 mg) and Rs 1,840 (12.5
mg) per month".
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/glenmark-launches-kidney-cancer-treatment-drug-in-india-priced-96-lower-than-innovator-brand/articleshow/80969368.cms
generic version of Sunitinib oral capsules to treat kidney cancer in
India. The drug is launched at a MRP that is approximately 96 per cent
lower than the MRP (maximum retail price) compared to the innovator
brand, priced at Rs 7,000 (50 mg), Rs 3,600 (25 mg) and Rs 1,840 (12.5
mg) per month".
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/glenmark-launches-kidney-cancer-treatment-drug-in-india-priced-96-lower-than-innovator-brand/articleshow/80969368.cms
Comments
Post a Comment